Scientists Determine 3-D Crystal Structure Of Cancer-Causing Protein

February 14, 1997

Work Links to Discovery Made at Rockefeller 86 Years Ago

The three-dimensional picture of a cancer-causing protein illuminates how a mutated gene transforms cells into cancer, report scientists from the Howard Hughes Medical Institute at The Rockefeller University in the Feb. 13 Nature. The determination of this structure clarifies earlier models that sought to explain how the gene, called src, works and offers new information for designing drug therapies to fight cancers.

"These findings help to explain how tinkering with just one protein produces changes in cell behavior," said senior author John Kuriyan, Ph.D., Rockefeller professor and HHMI investigator. "This gives us a better understanding of the breakdown of controls that lead to cancer." Kuriyan heads one of the university's laboratories of Molecular Biophysics.

Cells rely on proteins to regulate their differentiation and growth. Mutations that alter the normal function of control proteins result in unchecked growth and differentiation--cancer. In a process called phosphorylation--often the first step of signal transmission inside a cell--an enzyme called a kinase attaches a highly charged phosphate group to a tyrosine, one of the 20 amino acids that make proteins, acting as a molecular switch that turns proteins off and on.

In this study, Kuriyan and co-workers Frank Sicheri, Ph.D., and Ismail Moarefi, Ph.D., determined the three-dimensional structure of Hck, one member of the Src family of very closely related tyrosine kinases, named for src, the first oncogene that was found to be the mutated form of a cellular protein. The Src family plays an important role in regulating the body's immune system and other cellular behavior. Src is found in nearly all cells of the body, but Hck primarily arises in cells related to the immune system, such as macrophages and B cells. In a related paper published in this issue of Nature, a team of scientists led by Stephen Harrison, Ph.D., an HHMI investigator at Children's Hospital in Boston, determined the crystal structure of Src.

In the cellular signaling event known as signal transduction, proteins cluster together on the surface of the cell in response to an external signal. This clustering is mediated by modular units that carry the phosphorylated tyrosines, or phosphotyrosines. One of these modular units, Src homology (SH) domain 2, is a signaling molecule that enables interactions and contains docking units. Normally, Hck, like the other members of the Src family, is "off," folded into a position much like a snake biting its own tail. In this closed position, SH2 binds to the phosphotyrosine in Hck's tail, but if this phosphotyrosine is deleted, the structure opens up, enabling Src to seek out other proteins to phosphorylate.

Scientists have long known that, in the viral form of the Src protein, the phosphotyrosine is missing, resulting in the transformation of normal cells into cancerous ones. The work by the Hughes-Rockefeller team confirms earlier models that showed the change in the protein's shape that enables it to transform cells, but shows, unexpectedly, that it is the SH3 domain that is the prime controller of the enzyme's activity. "The role of the SH2 domain appears to be to set up the binding site on the enzyme's catalytic machinery for proper binding of the SH3 domain," said Kuriyan.

In a companion paper in the same issue of Nature, Kuriyan, Sicheri and Moarefi collaborated with researchers Michelle LaFevre-Bernt, B.S., and W. Todd Miller, Ph.D., from the State University of New York at Stony Brook to study the interaction of Hck with an HIV-1 protein called Nef. The results of this studied confirmed the finding that SH3 plays an important role in the activation of Hck. "We know that Nef binds tightly to the SH3 domain of Hck," said Kuriyan. "Nef turns out to be a potent activator of Hck activity."

This work was funded by the Howard Hughes Medical Institute. In addition, Miller received support from the federal government's National Institutes of Health. Sicheri is a fellow of the Human Frontiers Science Program.

On a historical note, in work that would win him a Nobel Prize in 1966, Rockefeller's Peyton Rous, M.D., Sc.D., discovered in 1911 that a virus causes cancer in chickens. This virus, which became known as the Rous sarcoma virus, was later found to contain a gene with the capacity to transform healthy cells into cancer cells. The gene, called src, was identified as a mutated version of a gene that is normally present in cells. Rockefeller's Hidesaburo Hanafusa, Ph.D., Leon Hess Professor, was among the first to provide direct evidence for the existence of Src in normal cells. Rockefeller faculty have made significant scientific achievements, including the discovery that DNA is the carrier of genetic information and the launching of the scientific field of modern cell biology. The university has ties to 19 Nobel laureates, including the university president, Torsten Wiesel, M.D., who received the prize in 1981. Recently, the university created four centers to foster collaborations among scientists from complementary fields to pursue investigations of Alzheimer's Disease, human genetics, neurosciences and the links between physics and biology.
-end-


Rockefeller University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.